Intra-Cellular Therapies Inc • ITCI

Capital at risk.

About Intra-Cellular Therapies Inc
Ticker
info
ITCI
Trading on
info
NASDAQ
ISIN
info
US46116X1019
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Dr. Sharon Mates Ph.D.
Headquarters
info
135 Route 202/206, Bedminster, NJ, United States, 07921
Employees
info
860
Website
info
intracellulartherapies.com
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Metrics
BasicAdvanced
Market cap
info
$14B
P/E ratio
info
-
EPS
info
-$0.73
Dividend Yield
info
0.00%
Beta
info
0.46
Forward P/E ratio
info
158.73
EBIDTA
info
$-116M
Ex dividend date
info
-
Price & volume
Market cap
info
$14B
Average daily volume
info
-
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
158.73
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
20.63
Price to book
info
12.23
Earnings
EPS
info
-$0.73
EPS estimate (current quarter)
info
-$0.11
EPS estimate (next quarter)
info
-$0.15
EBITDA
info
$-116M
Revenues (TTM)
info
$681M
Revenues per share (TTM)
info
$6.60
Technicals
Beta
info
0.46
52-week High
info
$131.98
52-week Low
info
$80.83
50-day moving average
info
$129.34
200-day moving average
info
$93.12
Short ratio
info
1.2
Short %
info
2.54%
Management effectiveness
ROE (TTM)
info
-8.58%
ROA (TTM)
info
-6.96%
Profit margin
info
-10.97%
Gross profit margin
info
$388M
Operating margin
info
-14.66%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
50.80%
Share stats
Outstanding Shares
info
107M
Float
info
105M
Insiders %
info
2.48%
Institutions %
info
96.45%
Analyst Insights & forecasts
info

94% Buy

6% Hold

0% Sell

Based on information from 15 analysts.

Average price target

info
$132.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.16
-$0.32
50.00%
Q1 • 24Beat
-$0.16
-$0.19
15.79%
Q2 • 24Beat
-$0.25
-$0.20
-25.00%
Q3 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$175M
$-26.3M
-15.03%
Q3 • 24
$199M
$-16.9M
-8.48%
Q4 • 24
13.74%
-35.86%
-43.60%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.32B
$180M
13.56%
Q3 • 24
$1.37B
$218M
15.98%
Q4 • 24
3.21%
21.62%
17.84%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-26.5M
$-209M
$6.7M
$-27.2M
Q3 • 24
$-13.1M
$-150M
$5.6M
$-12.7M
Q4 • 24
-50.70%
-28.35%
-16.75%
-53.52%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Intra-Cellular Therapies Inc share?
Collapse

Intra-Cellular Therapies Inc shares are currently traded for undefined per share.

How many shares does Intra-Cellular Therapies Inc have?
Collapse

Intra-Cellular Therapies Inc currently has 107M shares.

Does Intra-Cellular Therapies Inc pay dividends?
Collapse

No, Intra-Cellular Therapies Inc doesn't pay dividends.

What is Intra-Cellular Therapies Inc 52 week high?
Collapse

Intra-Cellular Therapies Inc 52 week high is $131.98.

What is Intra-Cellular Therapies Inc 52 week low?
Collapse

Intra-Cellular Therapies Inc 52 week low is $80.83.

What is the 200-day moving average of Intra-Cellular Therapies Inc?
Collapse

Intra-Cellular Therapies Inc 200-day moving average is $93.12.

Who is Intra-Cellular Therapies Inc CEO?
Collapse

The CEO of Intra-Cellular Therapies Inc is Dr. Sharon Mates Ph.D..

How many employees Intra-Cellular Therapies Inc has?
Collapse

Intra-Cellular Therapies Inc has 860 employees.

What is the market cap of Intra-Cellular Therapies Inc?
Collapse

The market cap of Intra-Cellular Therapies Inc is $14B.

What is the P/E of Intra-Cellular Therapies Inc?
Collapse

The current P/E of Intra-Cellular Therapies Inc is null.

What is the EPS of Intra-Cellular Therapies Inc?
Collapse

The EPS of Intra-Cellular Therapies Inc is -$0.73.

What is the PEG Ratio of Intra-Cellular Therapies Inc?
Collapse

The PEG Ratio of Intra-Cellular Therapies Inc is 0.

What do analysts say about Intra-Cellular Therapies Inc?
Collapse

According to the analysts Intra-Cellular Therapies Inc is considered a buy.